康莱特注射液辅助安罗替尼对小细胞肺癌术后复发患者临床疗效和生存获益情况影响

Effect of conlett-assisted anrotinib on oncology efficacy and survival benefits of patients with SCLC recurrence after surgery

目的探讨康莱特注射液辅助安罗替尼治疗小细胞肺癌(SCLC)术后复发患者的临床疗效。方法回顾性收集2019年1月至2021年1月共80例SCLC术后复发患者临床资料,根据治疗方案分为对照组和观察组,每组各40例。对照组予安罗替尼治疗,观察组予康莱特注射液辅助安罗替尼治疗。以21 d为1个治疗周期,连续治疗2个周期。比较2组临床疗效、治疗前及治疗1、2个周期的肿瘤标志物[血清神经元特异性烯醇化酶(NSE)、血管内皮生长因子(VEGF)及癌胚抗原(CEA)]、免疫细胞[T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))、自然杀伤细胞(NK)]水平、卡氏评分(KPS)、无进展生存期(PFS)及不良事件发生率。结果观察组客观缓解率(ORR)与对照组比较无差异无统计学意义(P>0.05),疾病控制率(DCR)高于对照组(P<0.05);观察组治疗1、2个周期血清NSE、VEGF及CEA水平低于对照组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)及NK细胞高于对照组(P<0.05);观察组治疗1、2个周期KPS评分高于对照组(P<0.05);观察组PFS长于对照组(P<0.05)。观察组不良事件发生率与对照组比较差异无统计学意义(P>0.05),观察组不良事件总发生率有低于对照组的趋势,但差异无统计学意义(P>0.05)。结论康莱特注射液辅助安罗替尼治疗SCLC术后复发患者临床效果显著,能改善免疫功能,下调肿瘤标志物水平,有助于延长患者生存期,提高生活质量,且安全性较高。

AIM To investigate the clinical efficacy and survival benefits of conlett-assisted anrotinib in the treatment of postoperative recurrent small cell lung cancer(SCLC)patients.METHODS Clinical data of 80 patients with postoperative recurrence of SCLC from January 2019 to January 2021 were retrospectively collected and divided into control group and observation group according to treatment plan,with 40 cases in each group.The control group was treated with anrotinib,and the observation group was treated with conlett-assisted anrotinib.21 d was used as a treatment cycle for 2 consecutive cycles.Clinical efficacy,tumor markers[serum neuron specific enolase(NSE),vascular endothelial growth factor(VEGF)and carcinoembryonic antigen(CEA)],immune cells[T lymphocyte subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+)),natural killer cells(NK)],Karnofsky performance status(KPS),progression-free survival(PFS),and safety were also compared before treatment and after 1 and 2 treatment cycles.RESULTS The objective remission rate(ORR)in the observation group was not significantly different from that in the control group(P>0.05),while the disease control rate(DCR)was higher than that in the control group(P<0.05).The serum NSE,VEGF and CEA levels in the observation group were lower than those in the control group after 1 and 2 cycles of treatment,and the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and NK cells were higher than those in the control group(P<0.05).The KPS score in the observation group was higher than that in the control group after 1 and 2 cycles of treatment(P<0.05).The PFS in the observation group was longer than that in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse events between the observation group and the control group(P>0.05),and the overall incidence of adverse events in the observation group tended to be lower than that in the control group.CONCLUSION Conlett-assisted anrotinib in the treatment of SCLC patients with postoperative recurrence has significant disease control effect.It can improve immune function,downregulate the level of tumor markers,contribute to prolong the survival,enhance quality of life,and demonstrate a high level of safety.